Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Lung microbiota: a prognostic marker of COPD?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Lung microbiota: a prognostic marker of COPD?

Lung microbiota: a prognostic marker of COPD?

Lung condition
Pulmonology

Composition of the pulmonary microbiota could well become a marker of the severity of chronic obstructive pulmonary diseases. A team brought to light a correlation between the presence of some bacteria and prognosis at one year.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 08 January 2019
Updated 06 October 2021

 

Chronic obstructive pulmonary disease (COPD) affected 3.5 million people in France in 2010. It is responsible for over 100,000 hospitalizations per year for (sidenote: Data from the French Haute Autorité de Santé (HAS) ) . These episodes are associated with an increase of short- and medium-term mortality rates. Studies have shown that patients with COPD have a decreased lung microbiota diversity, and this dysbiosis has been cited as a potential cause of airway inflammation and decreased local immunity.

Diversity ensures a better prognosis

A new international study recently found a possible severity marker of COPD, that could identify patients at high risk of death. 102 patients hospitalized for AE were included in the study and their sputum was collected on Day 1. The microbiome was analyzed through 16S rRNA sequencing, but unfortunately it could not be compared to standard sputum cultures (cytobacteriological examination). Patients were then monitored to determine the survival rate one year after this hospitalization. According to different indices, there is an inverse linear correlation between microbiota diversity and one-year mortality: the more diverse the microbiota, the lower one-year mortality.

A dangerous bacterial combination

<>In this study, (sidenote: The technique used did not allow to identity relevant species from these two genera )  were discovered as having a strong prognostic potential. The first–Veillonella–is a bacterium from the oral commensal flora found in the lungs of adults. Its absence in the sputum of patients is associated to a 13-fold higher risk of death at one year, and Veillonella-positive (V+) patients have, in average, a shorter length of hospital stay than Veillonella-negative (V-) patients. Additionally, the presence of species from the Staphylococcus (S+) genus in the sputum is associated to a 7-fold higher risk of death at one year, and to longer hospital stays. A higher comorbidity in V‑/S+ patients was not detected: the combination of these two criteria is extremely unfavorable since V-/S+ patients are 85 times more likely to die within the first year than V+/S- patients. If these results are confirmed by other studies, screening for these two bacterial genera could thus become a “standard” test to identify high-risk patients.

 

Sources

Leitao Filho FS, Alotaibi NM, Ngan D et al. Sputum Microbiome is Associated With 1-Year Mortality Following COPD Hospitalizations. AJRCCM Articles in Press. 2019 May 15;199(10):1205-1213.

 

Tags
Dysbiosis COPD Chronic obstructive pulmonary disease Bronchi Lungs Staphylococcus Veillonella Pulmonary Expectoration

en_view en_sources

    Created 08 January 2019
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Lung condition

    Medical practice

    Pulmonology

    Content type

    News

    Continue reading

    News
    25.10.2022

    Antibiotics: Dr Jekyll and Mr Hyde

    Read the article
    02.03.2021

    Cervicovaginal microbiota: a marker for persistent papillomavirus infection?

    Read the article
    18.11.2020

    Gut microbiota signature for cirrhosis

    Read the article
    Actu PRO : Le microbiote buccal, facteur de risque de cancer pulmonaire ?
    13.04.2021

    Oral microbiota, a risk factor for lung cancer?

    Read the article
    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria
    02.06.2022

    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    21.03.2022

    Endometriosis and Microbiota: what are the links ?

    Read the article
    Antibiotiques : le mycobiote des nourrissons sous influence
    16.08.2022

    The effect of antibiotics on infant mycobiota

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    Microbiota 17 EN
    Check out our latest magazine
    The first 1000 days of life
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    13.09.2023

    Parkinson’s disease: Desulfovibrio bacteria have been found guilty

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article
    29.08.2023

    Ulcerative colitis: a randomized controlled trial highlights the positive effects of the Mediterranean diet

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo